Products
Atisnolerbart Biosimilar Monoclonal Antibody (Bet v 1) for Research
Cat No.: GMP-Bios-INN-1089
Anti-Bet v 1 therapeutic antibody (Pre-made Atisnolerbart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Atisnolerbart is a monoclonal antibody targeting the birch pollen allergen Bet v 1. It is developed by Regeneron for birch pollen allergy and allergic rhinitis. It is in Phase III clinical development as part of a three-antibody combination with bremzalerbart and umesolerbart.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1089-1mg | 1mg | 3090 |
| GMP-Bios-INN-1089-10mg | 10mg | |
| GMP-Bios-INN-1089-100mg | 100mg | |
| GMP-Bios-INN-1089-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Atisnolerbart biosimilar, Whole mAb: Anti-Bet v 1 therapeutic antibody |
| INN Name | Atisnolerbart |
| Target | Bet v 1 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | 7mxl:JK/7n0v:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | Regeneron |
| Conditions Approved | na |
| Conditions Active | Allergic rhinitis;Birch pollen allergy |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
